medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2021, Number 3

<< Back Next >>

Rev Latin Infect Pediatr 2021; 34 (3)

Brief review on nebulization in times of COVID-19

Larenas-Linnemann D, Hernández PR, García MJ

Language: Spanish
References: 30
Page: 135-141
PDF size: 214.88 Kb.


ABSTRACT

Asthma, a chronic bronchial disease, presents with exacerbations that merit immediate management with inhaled treatment that is frequently applied through nebulisations. However, the current concern about the airborne transmission of SARS-CoV-2 has led to suboptimal treatment for patients suffering an asthma attack due to fear of contagion. The subject is reviewed and recommendations based on the literature are provided.


REFERENCES

  1. Larenas-Linnemann D et al. Manejo integral del asma. 2021. En prensa.

  2. Carrillo G, Mendez-Domínguez N, Datta-Banik R, Figueroa-Lopez F, Estrella-Chan B, Alvarez-Baeza A et al. Asthma mortality and hospitalizations in Mexico from 2010 to 2018: Retrospective epidemiologic profile. Int J Environ Res Public Health. 2020; 17 (14): 5071.

  3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Accessed 01 January 2021] Available in: www.ginasthma.org.

  4. Solé D, Aranda CS, Wandalsen GF. Asthma: epidemiology of disease control in Latin America - short review. Asthma Res Pract. 2017; 3: 4.

  5. Fainardi V, Santoro A, Caffarelli C. Preschool wheezing: trajectories and long-term treatment. Front Pediatr. 2020; 8: 240.

  6. Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics. 2009; 123: e519-525.

  7. Kaiser SV, Huynh T, Bacharier LB, Rosenthal JL, Bakel LA, Parkin PC et al. Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis. Pediatrics. 2016; 137: e20154496.

  8. Wu Z, Bian X, Hui L, Zhang J. Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study. Exp Ther Med. 2020; 19 (3): 1665-1672.

  9. The science of aerosol drug delivery. En: Douglas S. Gardenhire, editor. A guide to aerosol delivery devices for respiratory therapists. 4th ed. USA: American Association for Respiratory Care; 2017, pp. 1-8.

  10. Área de asma de SEPAR; Área de enfermería de SEPAR; Departamento de asma ALAT. Consenso SEPAR-ALAT sobre terapia inhalada. Arch Bronconeumol. 2013; 49 (Suppl 1): 2-14.

  11. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B et al. European Respiratory Society Task Force on the use of nebulizers. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001; 18 (1): 228-242.

  12. Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir Med. 2020; 167: 105987.

  13. Murphy KR, Hong JG, Wandalsen G, Larenas-Linnemann D, El Beleidy A, Zaytseva OV et al. Nebulized inhaled corticosteroids in asthma treatment in children 5 years or younger: a systematic review and global expert analysis. J Allergy Clin Immunol Pract. 2020; 8 (6): 1815-1827.

  14. Longest W, Spence B, Hindle M. Devices for improved delivery of nebulized pharmaceutical aerosols to the lungs. J Aerosol Med Pulm Drug Deliv. 2019; 32 (5): 317-339.

  15. Araújo ADD, Correia-de-Sousa J. COPD: Will there be room for nebulisers after the current COVID-19 pandemic? Open Respiratory Archives 2020; 2 (4): 265-266.

  16. Amirav I, Newhouse MT. Transmission of coronavirus by nebulizer: a serious, underappreciated risk. CMAJ. 2020; 192 (13): E346.

  17. Benge CD, Barwise JA. Aerosolization of COVID-19 and contamination risks during respiratory treatments. Fed Pract. 2020; 37 (4): 160-163.

  18. Sociedad Española de Neumología y Cirugía Torácica. GEMA 5.0. Guía española para el manejo del asma. [Consulta 29 Diciembre 2020] Disponible en: https://semg.es/images/documentos/GEMA_5.0.pdf.

  19. Treatment options for COVID-19. En: Joseph T, editor. International Pulmonologist's Consensus on COVID-19. 2nd. ed. India: 2020, pp. 34-43.

  20. Gobierno del Reino Unido. COVID-19: Guidance for the remobilisation of services within health and care settings. Infection prevention and control recommendations. [Accessed 02 January 2021] Available in: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/910885/COVID-19_Infection_prevention_and_control_guidance_FINAL_PDF_20082020.pdf.

  21. NICE. COVID-19 rapid guideline: severe asthma. [Accessed 02 January 2021] Available in: https://www.nice.org.uk/guidance/ng166.

  22. Banothu KK, Bhat JI, Das RR, Dhochak N, Ghimire JJ, Goyal JP et al. Expert opinion on restoration of pediatric pulmonology services during the SARS-CoV-2 pandemic. Indian Pediatr 2020; 57 (11): 1055-1059.

  23. Levin M, Ansotegui IJ, Bernstein J, Chang YS, Chikhladze M, Ebisawa M et al. Acute asthma management during SARS-CoV-2-pandemic 2020. World Allergy Organ J. 2020; 13 (5): 100125.

  24. Sethi S, Barjaktarevic IZ, Tashkin DP. The use of nebulized pharmacotherapies during the COVID-19 pandemic. Ther Adv Respir Dis. 2020; 14: 1753466620954366.

  25. Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RF Jr et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol. 2008; 122 (6): 1127-1135 e8.

  26. Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF Jr et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med. 2011; 365 (21): 1990-2001.

  27. Volovitz B, Soferman R, Blau H, Nussinovitch M, Varsano I. Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes. J Allergy Clin Immunol. 1998; 101 (4 Pt 1): 464-469.

  28. Larenas-Linnemann D, Salas-Hernandez J, Vazquez-Garcia JC, Ortiz-Aldana I, Fernandez-Vega M, Del Rio-Navarro BE et al. Mexican Asthma Guidelines: GUIMA 2017. Revista Alergia México. 2017; 64 Suppl 1: s11-s128.

  29. De Blic J, Delacourt C, Le Bourgeois M, Mahut B, Ostinelli J, Caswell C et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol. 1996; 98 (1): 14-20.

  30. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020; 324 (8): 782-793.




2020     |     www.medigraphic.com